220 related articles for article (PubMed ID: 17226115)
1. Improved prediction of relapse of Graves' thyrotoxicosis by combined determination of TSH receptor and thyroperoxidase antibodies.
Schott M; Eckstein A; Willenberg HS; Nguyen TB; Morgenthaler NG; Scherbaum WA
Horm Metab Res; 2007 Jan; 39(1):56-61. PubMed ID: 17226115
[TBL] [Abstract][Full Text] [Related]
2. Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves' disease.
Schott M; Morgenthaler NG; Fritzen R; Feldkamp J; Willenberg HS; Scherbaum WA; Seissler J
Horm Metab Res; 2004 Feb; 36(2):92-6. PubMed ID: 15002058
[TBL] [Abstract][Full Text] [Related]
3. Prediction of remission or relapse for Graves' hyperthyroidism by the combined determination of stimulating, blocking and binding TSH-receptor antibodies after the withdrawal of antithyroid drug treatment.
Wallaschofski H; Miehle K; Mayer A; Tuschy U; Hentschel B; Paschke R
Horm Metab Res; 2002 Jul; 34(7):383-8. PubMed ID: 12189586
[TBL] [Abstract][Full Text] [Related]
4. Relevance of TSH receptor stimulating and blocking autoantibody measurement for the prediction of relapse in Graves' disease.
Schott M; Minich WB; Willenberg HS; Papewalis C; Seissler J; Feldkamp J; Bergmann A; Scherbaum WA; Morgenthaler NG
Horm Metab Res; 2005 Dec; 37(12):741-4. PubMed ID: 16372227
[TBL] [Abstract][Full Text] [Related]
5. Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves' disease after withdrawal of antithyroid treatment.
Quadbeck B; Hoermann R; Hahn S; Roggenbuck U; Mann K; Janssen OE
Horm Metab Res; 2005 Dec; 37(12):745-50. PubMed ID: 16372228
[TBL] [Abstract][Full Text] [Related]
6. Clinical value of M22-based assays for TSH-receptor antibody (TRAb) in the follow-up of antithyroid drug treated Graves' disease: comparison with the second generation human TRAb assay.
Massart C; Gibassier J; d'Herbomez M
Clin Chim Acta; 2009 Sep; 407(1-2):62-6. PubMed ID: 19576193
[TBL] [Abstract][Full Text] [Related]
7. Determination of the levels of anti-thyroid-stimulating hormone receptor antibody with thyroid peroxidase antibody in Omani patients with Graves' disease.
Alnaqdy A; Al-Maskari M
Med Princ Pract; 2005; 14(4):209-12. PubMed ID: 15961927
[TBL] [Abstract][Full Text] [Related]
8. TSH receptor antibody (TRAb) assays based on the human monoclonal autoantibody M22 are more sensitive than bovine TSH based assays.
Zöphel K; Roggenbuck D; von Landenberg P; Wunderlich G; Grüning T; Kotzerke J; Lackner KJ; Rees Smith B
Horm Metab Res; 2010 Jan; 42(1):65-9. PubMed ID: 19830651
[TBL] [Abstract][Full Text] [Related]
9. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease.
Quadbeck B; Hoermann R; Roggenbuck U; Hahn S; Mann K; Janssen OE;
Thyroid; 2005 Sep; 15(9):1047-54. PubMed ID: 16187913
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the 2nd generation radio-receptional assay for anti-TSH receptor antibodies (TRAb) in autoimmune thyroid diseases. Comparison with 1st generation and anti-thyroperoxidase antibodies (AbTPO).
Giovanella L; Ceriani L; Garancini S
Q J Nucl Med; 2001 Mar; 45(1):115-9. PubMed ID: 11456370
[TBL] [Abstract][Full Text] [Related]
11. TSH receptor antibodies for confirming the diagnosis and prediction of remission duration, in newly diagnosed Graves' disease patients.
Aleksić A; Aleksić Z; Stojanović M
Hell J Nucl Med; 2009; 12(2):146-50. PubMed ID: 19675869
[TBL] [Abstract][Full Text] [Related]
12. Impact of smoking on the course of Graves' disease after withdrawal of antithyroid drugs.
Quadbeck B; Roggenbuck U; Janssen OE; Hahn S; Mann K; Hoermann R;
Exp Clin Endocrinol Diabetes; 2006 Sep; 114(8):406-11. PubMed ID: 17039420
[TBL] [Abstract][Full Text] [Related]
13. Clinical value of the first automated TSH receptor autoantibody assay for the diagnosis of Graves' disease (GD): an international multicentre trial.
Schott M; Hermsen D; Broecker-Preuss M; Casati M; Mas JC; Eckstein A; Gassner D; Golla R; Graeber C; van Helden J; Inomata K; Jarausch J; Kratzsch J; Miyazaki N; Moreno MA; Murakami T; Roth HJ; Stock W; Noh JY; Scherbaum WA; Mann K
Clin Endocrinol (Oxf); 2009 Oct; 71(4):566-73. PubMed ID: 19170704
[TBL] [Abstract][Full Text] [Related]
14. Induction of TSH-receptor antibodies in patients with toxic multinodular goitre by radioiodine treatment.
Wallaschofski H; Müller D; Georgi P; Paschke R
Horm Metab Res; 2002 Jan; 34(1):36-9. PubMed ID: 11833000
[TBL] [Abstract][Full Text] [Related]
15. Anti-thyroid-stimulating hormone receptor antibodies determined by second-generation assay.
Mankaï A; Toumi D; Chadli-Chaieb M; Ghedira-Besbes L; Saad F; Ouertani M; Sfar H; Jeddi M; Chaieb L; Ghedira I
Clin Chem Lab Med; 2007; 45(1):26-9. PubMed ID: 17243910
[TBL] [Abstract][Full Text] [Related]
16. The quantitative measurement of autoantibodies to thyroglobulin and thyroid peroxidase by automated microparticle based immunoassays in Hashimoto's disease, Graves' disease and a follow-up study on postpartum thyroid disease.
Gilmour J; Brownlee Y; Foster P; Geekie C; Kelly P; Robertson S; Wade E; Braun HB; Staub U; Michel G; Lazarus JH; Parkes AB
Clin Lab; 2000; 46(1-2):57-61. PubMed ID: 10745983
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of the 2nd generation assay for anti-TSH receptor antibodies to differentiate relapse of Graves' thyrotoxicosis from development of painless thyroiditis after antithyroid drug treatment for Graves' disease.
Izumi Y; Takeoka K; Amino N
Endocr J; 2005 Aug; 52(4):493-7. PubMed ID: 16127219
[TBL] [Abstract][Full Text] [Related]
18. [Antibodies against TSH receptors (TRAb) as indicators in prognosing the effectiveness of Tiamazol therapy for Grave's Disease].
Bojarska-Szmygin A; Ciechanek R
Wiad Lek; 2003; 56(7-8):303-7. PubMed ID: 14969154
[TBL] [Abstract][Full Text] [Related]
19. [Individual outcome monitoring of TSH receptor antibody level for predicting the prognosis of Graves' disease].
Rink T; Holle LH; Schroth HJ; Garth H
Nuklearmedizin; 1998 May; 37(3):90-4. PubMed ID: 9604228
[TBL] [Abstract][Full Text] [Related]
20. Comparison of M22-based ELISA and human-TSH-receptor-based luminescence assay for the measurement of thyrotropin receptor antibodies in patients with thyroid diseases.
Liu C; Hermsen D; Domberg J; Graeber C; Hautzel H; Duan Y; Xu KF; Liu CP; Mao XD; Cupisti K; Scherbaum WA; Schott M
Horm Metab Res; 2008 Jul; 40(7):479-83. PubMed ID: 18504673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
